Literature DB >> 1301967

A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.

J E Hunt1, H P McNeil, G J Morgan, R M Crameri, S A Krilis.   

Abstract

Anticardiolipin antibodies (aCL) purified from patients with autoimmune disease have recently been shown to interact with a phospholipid-binding plasma protein, beta 2-glycoprotein I (beta 2-GPI). The aim of this study was to determine whether aCL purified from patients with infection also interact with beta 2-GPI. aCL purified from 23 patients with malaria, infectious mononucleosis, tuberculosis, hepatitis A or syphilis did not require the presence of beta 2-GPI to bind cardiolipin (CL). In contrast, aCL were purified from 11 out of 12 patients with autoimmune disease that bound CL only in the presence of beta 2-GPI. Thrombotic complications appear to be associated with aCL occurring in autoimmune disease but not with aCL associated with infections. We postulate that this increased risk of thrombosis in the autoimmune group may be due to the presence of aCL that bind CL in association with beta 2-GPI, a plasma protein with anticoagulant activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301967     DOI: 10.1177/096120339200100204

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  50 in total

Review 1.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 2.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 3.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 4.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

5.  Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay.

Authors:  Yan Ye; Zhigang Hu; Jie Liu; Guoqian Chen; Yaohong Zhou; Lei Yu
Journal:  Clin Rheumatol       Date:  2012-06-10       Impact factor: 2.980

6.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 7.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Authors:  Barton F Haynes; M Anthony Moody; Laurent Verkoczy; Garnett Kelsoe; S Munir Alam
Journal:  Hum Antibodies       Date:  2005

8.  High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P. vivax malaria.

Authors:  C A Facer; G Agiostratidou
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

10.  Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria.

Authors:  P H Jakobsen; S D Morris-Jones; L Hviid; T G Theander; M Høier-Madsen; R A Bayoumi; B M Greenwood
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.